Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection

Clinical Cancer Research

Volumn 12, Issue 7 I, 2006, Pages 2109-2116

  Urakami, Shinji ^a   Shiina, Hiroaki ^b   Enokida, Hideki ^a   Kawakami, Toshifumi ^a   Kawamoto, Ken ^a   Hirata, Hiroshi ^a   Tanaka, Yuichiro ^a   Kikuno, Nobuyuki ^a   Nakagawa, Masayuki ^c   Igawa, Mikio ^b   Dahiya, Rajvir ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SHIMANE UNIVERSITY   (Japan)

^c KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PROTEIN DKK 3; PROTEIN INHIBITOR; PROTEIN SFRP 1; PROTEIN SFRP 2; PROTEIN SFRP 4; PROTEIN SFRP 5; PROTEIN WIF 1; UNCLASSIFIED DRUG; WNT PROTEIN;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER DIAGNOSIS; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; EPIGENETICS; FEMALE; GENE SEQUENCE; HUMAN; HUMAN TISSUE; MALE; METHYLATION; MULTIGENE FAMILY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; URINE SEDIMENT;

CARCINOMA, TRANSITIONAL CELL; CARRIER PROTEINS; DNA METHYLATION; EYE PROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; MULTIVARIATE ANALYSIS; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 33646247418     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2468     Document Type: Article

References (28)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Holmang S, Hedelin H, Anderstrom C, et al. Recurrence and progression in low grade papillary urothelial tumors. J Urol 1999;162:702-7.
3. Chopin DK, Gattegno B. Superficial bladder tumors. Eur Urol 2002;42:533-41.
4. van Rhijn BW, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 2005;47:736-48.
5. Esteller M. Dormant hypermethylated tumour suppressor genes: questions and answers. J Pathol 2005;205:172-80.
6. Das PM, Singal R. DNA methylation and cancer. J Clin Oncol 2004;22:4632-42.
7. Dulaimi E, Uzzo RG, Greenberg RE, et al. Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin Cancer Res 2004;10:1887-93.
8. Chan MW, Chan LW, Tang NL, et al. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res 2002;8:464-70.
9. Kawano Y, Kypta R. Secreted antagonists of the Wnt signalling pathway. J Cell Sci 2003;116:2627-34.
10. Stoehr R, Wissmann C, Suzuki H, et al. Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. Lab Invest 2004;84:465-78.
11. Hsieh SY, Hsieh PS, Chiu CT, et al. Dickkopf-3/REIC functions as a suppressor gene of tumor growth. Oncogene 2004;23:9183-9.
12. Suzuki H, Watkins DN, Jair KW, et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 2004;36:417-22.
13. Urakami S, Shiina H, Enokida H, et al. Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/β-catenin signaling pathway. Clin Cancer Res 2006;12:383-91.
14. Sobin LH, Wittekind Ch, editors. TNM classification of malignant tumours, 6th ed. Geneva: UICC; 2002.
15. Dahiya R, Lee C, McCarville J, et al. High frequency of genetic instability of microsatellites in human prostatic adenocarcinoma. Int J Cancer 1997;72:762-7.
16. Enokida H, Shiina H, Igawa M, et al. CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer. Cancer Res 2004;64:5956-62.
17. Shiina H, Breault JE, Basset WW, et al. Functional Loss of the γ-catenin gene through epigenetic and genetic pathways in human prostate cancer. Cancer Res 2005;65:2130-8.
18. Suzuki H, Gabrielson E, Chen W, et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 2002;31:141-9.
19. Lodygin D, Epanchintsev A, Menssen A, et al. Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res 2005;65:4218-27.
20. Mazieres J, He B, You L, et al. Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res 2004;64:4717-20.
21. Zou H, Molina JR, Harrington JJ, et al. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus. Int J Cancer 2005;116:584-91.
22. Enokida H, Shiina H, Urakami S, et al. Multigene methylation analysis for detection and staging of prostate cancer. Clin Cancer Res 2005;11:6582-8.
23. Marsit CJ, Karagas MR, Andrew A, et al. Epigenetic inactivation of SFRP genes and TP53 alteration act jointly as markers of invasive bladder cancer. Cancer Res 2005;65:7081-5.
24. Ray A, Ho M, Ma J, et al. A clinicobiological model predicting survival in medulloblastoma. Clin Cancer Res 2004;10:7613-20.
25. Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93:9821-6.
26. Goessl C, Krause H, Muller M, et al. Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res 2000;60:5941-5.
27. Battagli C, Uzzo RG, Dulaimi E, et al. Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. Cancer Res 2003;63:8695-9.
28. Muller HM, Oberwalder M, Fiegl H, et al. Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet 2004;363:1283-5.